Pharma: Page 4

  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By • Feb. 15, 2024
  • Niesha Foster, Pfizer
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    ‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

    The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

    By • Feb. 14, 2024
  • biotech market Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.  

    By PharmaVoice staff
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024
  • vials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 questions hanging over the Novo-Catalent deal

    As backlash builds for the recently announced matchup, critical questions remain over its impact.

    By Kelly Bilodeau • Feb. 13, 2024
  • Brain MRI
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    A new (old) mind-opening tool in the fight against Alzheimer’s disease

    A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

    By Kelly Bilodeau • Feb. 12, 2024
  • Yoshi Shitaka
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Astellas’ science chief on the leap into new technologies

    After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.

    By • Feb. 9, 2024
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

    While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

    By • Feb. 8, 2024
  • anti-vaccine protestors with a stop vaccines sign on street
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Pharma has a misinformation problem — and execs could be on the hook

    Investment heavyweights BlackRock and Glass Lewis want compensation clawbacks on execs who don’t protect a company’s reputation. 

    By Kelly Bilodeau • Feb. 7, 2024
  • Pill drug money balance
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    ‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap

    The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.

    By • Feb. 6, 2024
  • Empty congressional chamber
    Image attribution tooltip
    Brendan Hoffman via Getty Images
    Image attribution tooltip

    Government hits patent thickets on multiple fronts

    Patent thickets are the latest target in lawmakers' bid to lower drug prices.

    By Alexandra Pecci • Feb. 5, 2024
  • syringe dollar sign shadow
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Could Novo, Lilly become first trillion-dollar healthcare companies?

    Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

    By • Feb. 2, 2024
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Merck keeps deal focus with Keytruda patent cliff on horizon

    The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

    By Ned Pagliarulo • Feb. 1, 2024
  • Pfizer CEO Albert Bourla
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?

    In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.

    By • Feb. 1, 2024
  • AZ vaccine
    Image attribution tooltip
    Ricardo Ceppi via Getty Images
    Image attribution tooltip

    Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

    Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

    By Alexandra Pecci • Jan. 30, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    CAR-T developers respond to FDA black box warning

    Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.

    By Kelly Bilodeau • Jan. 30, 2024
  • A blood sample of HER2 for breast cancer diagnosis.
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images
    Image attribution tooltip

    AstraZeneca, Daiichi aim for first pan-tumor ADC approval

    A “tumor agnostic” FDA approval for the companies’ Enhertu would break new ground for antibody-drug conjugates. 

    By Ben Fidler • Jan. 29, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By • Jan. 26, 2024
  • 2024 outlook
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The biggest questions hanging over pharma in 2024

    Key trends on the horizon in the life sciences this year.

    By • Jan. 25, 2024
  • King Charles III
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

    The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

    By • Jan. 25, 2024
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images
    Image attribution tooltip

    J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

    Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

    By • Jan. 24, 2024
  • MRI machine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Breast cancer tops list of most studied diseases

    The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

    By Kelly Bilodeau • Jan. 24, 2024
  • Coronavirus
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    The hunt for an elusive universal coronavirus vaccine

    A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

    By Alexandra Pecci • Jan. 22, 2024
  • Chris Arendt
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip

    Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

    Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

    By • Jan. 19, 2024
  • Pharma progress
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How to make 2024 a banner year for biopharma, despite the headwinds

    Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

    By • Jan. 18, 2024
  • Covid doctor
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    An enduring COVID mystery: Why some do fine and others die

    The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

    By Alexandra Pecci • Jan. 17, 2024